TABLE 1.
Characteristics of HIV-infected and uninfected women (control group).
| Characteristics | HIV-infected | TDF exposed | % | HIV-uninfected | Control | p-value |
|---|---|---|---|---|---|---|
| Number of participants, (n) | 30.0 | - | - | 30.0 | - | |
| Median age (IQR), years | 52.0 | 49.0–59.0 | - | 57.0 | 53.7–63.3 | 0.008§ |
| Median BMI (IQR), kg/m2 | 20.5 | 18.2–28.9 | - | 24.4 | 19.4–33.5 | 0.333 |
| Median weight (IQR), kg | 52.5 | 44.0–68.7 | - | 60.4 | 49.1–84.3 | 0.179 |
| Median TDF ART exposure (months) | 16.6 | 8.8–23.4† | - | - | - | - |
| Median non–TDF ART exposure (months) | 24.5 | 16.8–43.8‡ | - | - | - | - |
| Median time since HIV diagnosis (months) | 31.0 | 22.0–53.5‡ | - | - | - | - |
| Other antiretroviral drugs in regimen: | ||||||
| Lamivudine | 30.0 | - | 100.0 | - | - | - |
| Efavirenz | 30.0 | - | 100.0 | - | - | - |
| Concomitant medication: | ||||||
| Hydrochlorothiazide | 1.0 | - | 3.3 | None | - | - |
| Nifedipine | 1.0 | - | 3.3 | None | - | - |
| Underlying disease: | ||||||
| Hypertension | 2.0 | - | 6.7 | None | - | - |
†
n = 24 (Four participants declined to provide consent to access their medical records, and information from two medical records was missing);
‡
n = 22 (Four participants declined to provide consent to access their medical records, and information from four medical records was missing);
§
The age was already adjusted for with BMI when selecting controls via propensity score matching.